{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:11:12Z","timestamp":1759702272073},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":6323,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1992,1]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Essential thrombocythemia, a myeloproliferative disorder of clonal origin, is often associated with various clinical manifestations resulting from thromboembolic or hemorrhagic complications. The long\u2010established successful method of treatment with cytotoxic agents or radioactive phosphorus has recently been superseded by interferon alpha. We treated 14 symptomatic patients with 5 times 10<jats:sup>6<\/jats:sup> IU recombinant interferon\u03b1\u20102b s.c. daily. 12\/14 pts responded within 14\u201375 days. When platelet counts decreased to below 450 g\/l the frequency of administration was reduced stepwise. 7 patients remained in CR during this reduction phase and treatment was stopped in 5 pts after 12\u201332 months. Until now, 3 of them are still in continuous good PR without any drug therapy and free of symptoms for 3+, 19+ and 36+ months. Continuous response during maintenance was associated with age, initial platelet count and time required to reduce platelet counts to &lt;450 g\/l.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1992.tb01790.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T11:38:17Z","timestamp":1279453097000},"page":"33-36","source":"Crossref","is-referenced-by-count":20,"title":["Remission may continue after termination of rIFN\u03b1 \u20102b treatment for essential thrombocythemia"],"prefix":"10.1111","volume":"48","author":[{"given":"H.","family":"Kasparu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bernhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow PJ","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106077"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1657135","article-title":"Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders","volume":"47","author":"Pareti FI","year":"1982","journal-title":"Thromb Haemostas"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880315)61:6<1207::AID-CNCR2820610625>3.0.CO;2-4"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V63.1.51.51","article-title":"Therapy of essential thrombocythemia with thiotepa and chlorambucil","volume":"63","author":"Case DC","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1985.tb02270.x"},{"key":"e_1_2_1_8_2","first-page":"306","article-title":"Pipobroman therapy of essential thrombocythemia","volume":"37","author":"Mazzucconi M.","year":"1986","journal-title":"Scand J Haematol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V63.4.866.866","article-title":"Blastic transformation of essential thrombocythemia: Dual expression of myelomonoblastic\/megakaryoblastic phenotypes","volume":"63","author":"Frei\u2010Lahr D.","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01720201"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92625-6"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90005-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-6-789"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92142-9"},{"key":"e_1_2_1_17_2","unstructured":"KasparuH. ReisnerR. BernhartM. PittermannE. KriegerO. LutzD.First results of the treatment of essential thrombocythemia with recombinant alpha\u20102b interferon. Proc. XXII Congress of the International Society of Hematology Milan August 28September 2 1988 page.259."},{"issue":"52","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0609.1990.tb00899.x","article-title":"Therapy of essential thrombocythemia with alpha \u2010 interferon: Results and prospects","volume":"45","author":"Lazzarino M.","year":"1990","journal-title":"Eur J Haematol"},{"key":"e_1_2_1_19_2","first-page":"177","article-title":"Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S.","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02924.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(86)90411-5"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90077-1"},{"key":"e_1_2_1_23_2","first-page":"648","article-title":"Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia","volume":"2","author":"Blennerhassett GT","year":"1988","journal-title":"Leukemia"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199009050983"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330106"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.00001.x-i1"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1992.tb01790.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1992.tb01790.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T14:41:29Z","timestamp":1698072089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1992.tb01790.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1992,1]]}},"alternative-id":["10.1111\/j.1600-0609.1992.tb01790.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1992.tb01790.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,1]]}}}